Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma

Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer

(2018) Masahiro Takeuchi et al.   IMMUNOLOGY LETTERS

High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma

(2018) Xiaofang Guo et al.   Translational Oncology

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

(2018) Jun Gong et al.   Journal for ImmunoTherapy of Cancer

Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy

(2018) Neus Martinez-Bosch et al.   Cancers

PD-L1 Expression in Pancreatic Cancer

(2017) Lei Zheng   JNCI-Journal of the National Cancer Institute

Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis

(2017) Xiuwen Lan et al.   OncoTargets and Therapy

PD-L1 Expression in Pancreatic Cancer

(2017) Lei Zheng   JNCI-Journal of the National Cancer Institute

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

(2017) Stephan Kruger et al.   OncoImmunology

BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

(2017) Audrey Benyamine et al.   OncoImmunology

Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma

(2016) Shang-Yi Huang et al.   Oncotarget

BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia

(2016) Audrey Benyamine et al.   OncoImmunology

From bench to bedside a comprehensive review of pancreatic cancer immunotherapy

(2016) Paul R. Kunk et al.   Journal for ImmunoTherapy of Cancer

The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date

(2015) Katy K. Tsai et al.   DRUGS

Immune Therapy in GI Malignancies: A Review

(2015) Judy Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma

(2015) Lai Mun Wang et al.   Oncotarget

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

(2015) Cara L Haymaker et al.   OncoImmunology

Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study

(2014) Wanda K O’Neal et al.   Journal of Translational Medicine

Systemic treatment of advanced pancreatic cancer

(2012) Volker Heinemann et al.   CANCER TREATMENT REVIEWS

Analysis of serum and plasma identifies differences in molecular coverage, measurement variability, and candidate biomarker selection

(2012) Murtada Alsaif et al.   Proteomics Clinical Applications

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

(2010) Laurent Derré et al.   JOURNAL OF CLINICAL INVESTIGATION

High Expression of the Inhibitory Receptor BTLA in T-Follicular Helper Cells and in B-Cell Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia

(2009) Hasni M’Hidi et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY